Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 119,287 shares, an increase of 460.5% from the July 30th total of 21,284 shares. Currently, 2.2% of the company’s shares are short sold. Based on an average daily volume of 927,154 shares, the short-interest ratio is presently 0.1 days.

Silexion Therapeutics Stock Performance

NASDAQ:SLXN opened at $0.36 on Wednesday. Silexion Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $80.00. The company has a 50 day simple moving average of $2.00 and a two-hundred day simple moving average of $7.59. The company has a market capitalization of $2.03 million, a PE ratio of -0.01 and a beta of -0.25.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($21.20) by $16.03. Research analysts predict that Silexion Therapeutics will post -45.5 EPS for the current year.

Wall Street Analysts Forecast Growth

SLXN has been the topic of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold”.

Hedge Funds Weigh In On Silexion Therapeutics

A hedge fund recently bought a new position in Silexion Therapeutics stock. Ancora Advisors LLC purchased a new stake in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned about 7.14% of Silexion Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 10.95% of the company’s stock.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.